Drug Trial Radar · NCT06016738
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
510
Planned (sponsor's estimate)
Start
Nov 16, 2023
Primary completion
Oct 31, 2026
Study completion Feb 29, 2028
Sponsor
- Lead sponsor
- Olema Oncology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor.
Conditions
- Breast Cancer
- Advanced Breast Cancer
- Metastatic Breast Cancer
- ER Positive Breast Cancer
- HER2 Negative Breast Carcinoma
Interventions
PalazestrantDrug
Participants will be treated with palazestrant once daily on a 4 week (28 day) cycle. Doses evaluated in the dose-selection part will be 120 mg once daily and 90 mg once daily.
FulvestrantDrug
Participants will be treated with fulvestrant on C1D1, C1D15, and then on Day 1 of every subsequent 4 week (28 day) cycle
AnastrozoleDrug
Participants will be treated with anastrozole once daily on a 4 week (28 day) cycle
LetrozoleDrug
Participants will be treated with letrozole once daily on a 4 week (28 day) cycle
ExemestaneDrug
Participants will be treated with exemestane once daily on a 4 week (28 day) cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-Selection Part: Incidence of adverse eventsTime frame: From Date of Randomization up to 16 weeks
- Dose-Selection Part: Incidence of dose reductionTime frame: From Date of Randomization up to 16 weeks
- Dose-Selection Part: Incidence of drug discontinuationTime frame: From Date of Randomization up to 16 weeks
- Trial: Progression-Free Survival (PFS)Time frame: From Date of Randomization until Disease Progression or Death Due to Any Cause (estimated as up to 2 years)
Locations
233 sites in 26 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Tucson, Arizona
Clinical Trial Site
Fountain Valley, California
Clinical Trial Site
Glendale, California
Clinical Trial Site
La Jolla, California
Clinical Trial Site
Los Alamitos, California
Clinical Trial Site
Los Angeles, California
Clinical Trial Site
Whittier, California
Clinical Trial Site
Aurora, Colorado
Clinical Trial Site
Denver, Colorado
Clinical Trial Site
Golden, Colorado
Clinical Trial Site
Grand Junction, Colorado
Clinical Trial Site
Danbury, Connecticut
Clinical Trial Site
Newark, Delaware
Clinical Trials Site
Jacksonville, Florida
Clinical Trial Site
Margate, Florida
Clinical Trial Site
Orlando, Florida
Clinical Trial Site
Plantation, Florida
Clinical Trial Site
Tamarac, Florida
Clinical Trial Site
Atlanta, Georgia
Clinical Trial Site
Chicago, Illinois
Clinical Trial Site
Chicago, Illinois
Clinical Trial Site
Urbana, Illinois
Clinical Trial Site
Baton Rouge, Louisiana
Clinical Trial Site
New Orleans, Louisiana
Clinical Trial Site
Baltimore, Maryland
Clinical Trial Site
Boston, Massachusetts
Clinical Trial Site
Detroit, Michigan
Clinical Trial Site
Saint Louis Park, Minnesota
Clinical Trial Site
Woodbury, Minnesota
Clinical Trial Site
Lincoln, Nebraska
Clinical Trial Site
Farmington, New Mexico
Clinical Trial Site
New York, New York
Clinical Trial Site
Port Jefferson Station, New York
Clinical Trial Site
Dayton, Ohio
Clinical Trial Site
Toledo, Ohio
Clinical Trial Site
Portland, Oregon
Clinical Trial Site
Sayre, Pennsylvania
Clinical Trial Site
Nashville, Tennessee
Clinical Trial Site
Nashville, Tennessee
Clinical Trial Site
Nashville, Tennessee
Showing 40 of 233 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.